SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus

Angus Gill, Stephen P Gray, Karin Jandeleit-Dahm, Anna Watson

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

BACKGROUND: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90% of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. CONCLUSION: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.
Original languageEnglish
Number of pages9
JournalCurrent Diabetes Reviews
DOIs
Publication statusAccepted/In press - 17 Apr 2018

Keywords

  • SGLT-2
  • diabetic micro-and macrosvascular complications
  • cardiovascular and renoprotection
  • reactive oxygen species
  • sympathetic nerves

Cite this

@article{890d1c46af1b4d63bc188a97c798b504,
title = "SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus",
abstract = "BACKGROUND: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90{\%} of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. CONCLUSION: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.",
keywords = "SGLT-2, diabetic micro-and macrosvascular complications, cardiovascular and renoprotection, reactive oxygen species, sympathetic nerves",
author = "Angus Gill and Gray, {Stephen P} and Karin Jandeleit-Dahm and Anna Watson",
year = "2018",
month = "4",
day = "17",
doi = "10.2174/1573399814666180417121246",
language = "English",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers",

}

SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. / Gill, Angus; Gray, Stephen P; Jandeleit-Dahm, Karin; Watson, Anna.

In: Current Diabetes Reviews, 17.04.2018.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus

AU - Gill, Angus

AU - Gray, Stephen P

AU - Jandeleit-Dahm, Karin

AU - Watson, Anna

PY - 2018/4/17

Y1 - 2018/4/17

N2 - BACKGROUND: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90% of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. CONCLUSION: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.

AB - BACKGROUND: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90% of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. CONCLUSION: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.

KW - SGLT-2

KW - diabetic micro-and macrosvascular complications

KW - cardiovascular and renoprotection

KW - reactive oxygen species

KW - sympathetic nerves

UR - http://www.ncbi.nlm.nih.gov/pubmed/29663893

U2 - 10.2174/1573399814666180417121246

DO - 10.2174/1573399814666180417121246

M3 - Review Article

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

ER -